Hosted on MSN13h
MIND Diet and Cognitive Decline; Gene Therapy for Parkinson's; Curbing MS Fatigue
The MIND diet was associated with slower cognitive decline in both Black and white older adults, but relationships appeared ...
MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...
precisionmedicineonline6d
MeiraGTx to Discuss Parkinson's Gene Therapy Data With Regulators, Planning Phase III Trial
The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings ’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD ...
pharmaphorum7d
MeiraGTx plans to take Parkinson's gene therapy into phase 3
According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local ...
BioWorld7d
Meiragtx looks to a phase III in Parkinson’s
Gene therapy specialist Meiragtx Holdings plc got a market bump courtesy of newly released top-line data from its phase II bridging study in Parkinson’s disease. The six-month, three-arm randomized, ...
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints
On Tuesday, MeiraGTx Holdings plc (NASDAQ:MGTX) released topline data from its clinical bridging study of AAV-GAD for ...
The Pharma Letter7d
MeiraGTx rises on positive study of AAV-GAD for Parkinson’s disease
US clinical-stage genetic meds company MeiraGTx Holdings has released positive top-line data from its clinical bridging study ...
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
The primary study objective of safety and tolerability was metSignificant and clinically meaningful improvements from baseline demonstrated for ...
MeiraGTx Reports Positive AAV-GAD Trial Data For Parkinson's Disease; Stock Climbs
MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical-stage genetic medicines company, announced Tuesday positive top-line ...
MeiraGTx gains as gene therapy shows promise in Parkinson’s
MeiraGTx Holdings (MGTX) stock gains in premarket trading after positive trial results for the company's AAV-GAD gene therapy ...